VISCHER advises AFINUM on the acquisition of a majority stake in Ergon Informatik
VISCHER advises AFINUM on the acquisition of a majority stake in Ergon Informatik AG, a leading Swiss IT service provider with a focus on software development and digital security solutions.
The VISCHER team, led by Dr Jürg...
Proteomedix AG licenses manufacturing IP to Immunovia AB
VISCHER advised Proteomedix AG, a Swiss biotech subsidiary of Onconetix, Inc., on a licensing agreement with Immunovia AB, a Swedish pancreatic cancer diagnostics company.
AutoScout24 integrates the C2B business from CARAUKTION
VISCHER advised CARAUKTION on the takeover of the C2B business division, including the C2B auction platform, by AutoScout24.
VISCHER advises synaforce on the acquisition of ServerBase
The synaforce Group acquires ServerBase AG, an established Swiss cloud platform based in Bachenbülach in the Canton of Zurich. VISCHER acted as legal counsel to the synaforce Group on this transaction.
VISCHER advised Picanol in its acquisition of Osterwalder
Tessenderlo Group, through its group company Picanol NV, has acquired the activities of Osterwalder AG, a Swiss manufacturer of electric powder presses.
MCH Group and Bits & Pretzels establish joint venture
MCH Group and Bits & Pretzels are joining forces under the joint venture health.tech events AG and launching health.tech | global summit, a new international leading conference for digital innovations in healthcare.
HAYA Therapeutics Announces Collaboration with Eli Lilly
HAYA Therapeutics SA, a Swiss biotechnology company pioneering precision RNA-guided regulatory genome targeting therapeutics, announced a multi-year agreement with Eli Lilly and Company to apply HAYA’s advanced RNA-guided regulatory genome platform to support preclinical drug discovery efforts in obesity and related metabolic conditions.
Sale of T3 Pharmaceuticals AG to Boehringer Ingelheim
T3 Pharmaceuticals AG, a biotechnology company with its headquarter in Allschwil, Switzerland has been acquired by Boehringer Ingelheim, a leading family-owned, research-driven biopharmaceutical company based in Ingelheim, Germany...
LASCCO and Abionic enter license agreement with Fapon
LASCCO SA, a biomedical-technology company, and Abionic SA, a nanotechnology company, both based at the Biopôle of Lausanne, Switzerland, entered into a licensing agreement with Fapon Biotech, a global leading life sciences company, based in Dongguan, China, for the use of the pancreatic stone protein (PSP) biomarker for sepsis diagnosis in China.
Memo Therapeutics AG Raises CHF 25 Million Series C Financing to Complete Phase II Clinical Development of AntiBKV for BKV Infection in Renal Transplant Patients
Memo Therapeutics AG, a late-stage biotech company developing best-in-class therapeutic antibodies closed a CHF25 million series C financing round led by Pureos Bioventures.